Work

The implications of waiving local clinical trials for drugs in India: a double-edged sword?

Year: 2024

Type: article

Abstract: India's decision to waive local clinical trials for drugs approved in countries like the U.S., U.K., Japan, and the European Union represents a pivotal regulatory shift. While the move aims to expedite access to essential medications and enhance market availability, it raises significant concerns about patient safety, research and development (R&D), and broader healthcare implications.1

Source: The Lancet Regional Health - Southeast Asia

DOI: 10.1016/j.lansea.2024.100501

Author: Rajmohan Seetharaman

Institution: Mahatma Gandhi Mission Institute of Health Sciences

Language: English

Topic: Pharmaceutical Economics and Policy

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,000